A review of glucoregulatory hormones potentially applicable to the treatment of Alzheimer’s disease: mechanism and brain delivery

다국어 초록 (Multilingual Abstract)

Background Despite the accumulating research efforts, the current treatment of Alzheimer’s disease (AD) remains far from achieving any clinical success in modifying the underlying pathological conditions.
Area covered Therefore, it is an imminent task to discover more potent anti-AD drugs, as well as deepen the understanding of the disease mechanism. A group of potential drug candidates for the AD may be the hormones that involve in the glucose homeostasis and lipid metabolism, as the type 2 diabetes mellitus (T2DM) and obesity have been recognized as major risk factors of the AD.
Expert opinion Indeed, up to date, many researches have reported the potential therapeutic effects of the glucoregulatory hormones, such as GLP-1, adipokines (adiponectin, leptin), and ghrelin. However, despite their anti-AD activity, there remains a bottleneck challenge for their successful delivery to the brain. In the present review, we provide an overview of the therapeutic potentials of glucoregulatory hormones and their receptor agonists for the AD. In the latter part, we also discuss the delivery strategies across the blood brain barrier, with a particular focus on previous studies that used the Trojan horse technology.

참고문헌 (Reference)

1 Wang A, "[D-Leu-4]-OB3 and MA-[D-Leu-4]-OB3, small molecule synthetic peptide leptin mimetics, improve glycemic control in diet-induced obese(DIO)mice" 101 : 51-59, 2018

2 Grasso P, "[D-LEU-4]-OB3, a synthetic leptin agonist, improves hyperglycemic control in C57BL/6J ob/ob mice" 101 : 123-129, 2001

3 Saito Y, "Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1–40through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1–40/vector complex" 92 : 10227-10231, 1995

4 Gengler S, "Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice" 33 : 265-276, 2012

5 Graebner AK, "Understanding how discrete populations of hypothalamic neurons orchestrate complicated behavioral states" 9 : 111-, 2015

6 Pardridge WM, "Treatment of Alzheimer’s disease and blood–brain barrier drug delivery" 13 : 394-, 2020

7 Chen Z-L, "Transferrin-modified liposome promotes α-mangostin to penetrate the blood–brain barrier" 12 : 421-430, 2016

8 Bourassa P, "Transferrin receptor-mediated uptake at the blood–brain barrier is not impaired by Alzheimer’s disease neuropathology" 16 : 583-594, 2019

9 Tortorella S, "Transferrin receptor-mediated endocytosis : a useful target for cancer therapy" 247 : 291-307, 2014

10 Bien-Ly N, "Transferrin receptor(TfR)trafficking determines brain uptake of TfR antibody affinity variants" 211 : 233-244, 2014

11 Kim B-J, "Transferrin fusion technology : a novel approach to prolonging biological half-life of insulinotropic peptides" 334 : 682-692, 2010

12 Dennis MS, "Transferrin antibodies into the brain" 37 : 302-303, 2012

13 Watanabe T, "Therapeutic properties of the new phytochemical osmotin for preventing atherosclerosis" 4 : 4-, 2020

14 Bi G, "Therapeutic effect of transmembrane TAT-tCNTF via Erk and Akt activation using in vitro and in vivo models of Alzheimer’s disease" 11 : 1855-1865, 2018

15 Forny-Germano L, "The role of leptin and adiponectin in obesity-associated cognitive decline and Alzheimer’s disease" 12 : 1027-, 2019

16 Kim S, "The potential roles of ghrelin in metabolic syndrome and secondary symptoms of Alzheimer’s disease" 14 : 583097-, 2020

17 Sarko D, "The pharmacokinetics of cell-penetrating peptides" 7 : 2224-2231, 2010

18 Macdonald PE, "The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion" 51 : S434-S442, 2002

19 James J, "The effects of ulimorelin, a ghrelin agonist, on liquid gastric emptying and colonic transit in humans" 32 : e13784-, 2020

20 Maskery M, "The dual GLP-1/GIP receptor agonist DA4-JC shows superior protective properties compared to the GLP-1 analogue liraglutide in the APP/PS1 mouse model of Alzheimer’s disease" 35 : 1-11, 2020

21 Batista AF, "The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer’s disease" 245 : 85-100, 2018

22 Mcclean PL, "The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease" 31 : 6587-6594, 2011

23 Ballabh P, "The blood–brain barrier : an overview : structure, regulation, and clinical implications" 16 : 1-13, 2004

24 Yoon G, "The adiponectin homolog osmotin enhances neurite outgrowth and synaptic complexity via AdipoR1/NgR1 signaling in Alzheimer’s disease" 55 : 6673-6686, 2018

25 Lv M, "The GLP-1/GIP dual-receptor agonist DA5-CH inhibits the NF-κB inflammatory pathway in the MPTP mouse model of Parkinson’s disease more effectively than the GLP-1 single-receptor agonist NLY01" 11 : 2231-, 2021

26 Zhang C, "Tat-modified leptin is more accessible to hypothalamus through brain-blood barrier with a significant inhibition of body-weight gain in highfat-diet fed mice" 118 : 31-37, 2010

27 Meng T, "Tat-haFGF14–154 upregulates ADAM10 to attenuate the Alzheimer phenotype of APP/PS1 mice through the PI3K-CREB-IRE1α/XBP1 pathway" 7 : 439-452, 2017

28 Omori N, "Targeting of post-ischemic cerebral endothelium in rat by liposomes bearing polyethylene glycolcoupled transferrin" 25 : 275-279, 2003

29 Duro-Castano A, "Targeting Alzheimer’s disease with multimodal polypeptide-based nanoconjugates" 7 : eabf9180-, 2021

30 Yamauchi T, "Targeted disruption of AdipoR1 and AdipoR2causes abrogation of adiponectin binding and metabolic actions" 13 : 332-339, 2007

31 Gaillard PJ, "Targeted delivery across the blood–brain barrier" 2 : 299-309, 2005

32 Rao KS, "TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs" 29 : 4429-4438, 2008

33 Yemisci M, "Systemically administered brain-targeted nanoparticles transport peptides across the blood–brain barrier and provide neuroprotection" 35 : 469-475, 2015

34 Khafagy E-S, "Systemic and brain delivery of leptin via intranasal coadministration with cell-penetrating peptides and its therapeutic potential for obesity" 319 : 397-406, 2020

35 Nasir Abbas Bukhari S, "Synthetic curcumin analogs as inhibitors of β-amyloid peptide aggregation : potential therapeutic and diagnostic agents for Alzheimer’s disease" 15 : 1110-1121, 2015

36 Lugar CW, "Synthesis and biological evaluation of an orally active ghrelin agonist that stimulates food consumption and adiposity in rats" 14 : 5873-5876, 2004

37 Brubaker P, "Structure-function of the glucagon receptor family of G protein-coupled receptors : the glucagon, GIP, GLP-1, and GLP-2 receptors" 8 : 179-188, 2002

38 Kawai T, "Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist" 117 : 29959-29967, 2020

39 Miele M, "Structural and functional similarities between osmotin from Nicotiana tabacum seeds and human adiponectin" 6 : e16690-, 2011

40 Ariyasu H, "Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans" 86 : 4753-4758, 2001

41 Rhea EM, "Role of the blood-brain barrier in central nervous system insulin resistance" 13 : 521-, 2019

42 Boado RJ, "Reduction in brain heparan sulfate with systemic administration of an IgG Trojan horse–sulfamidase fusion protein in the mucopolysaccharidosis type IIIA mouse" 15 : 602-608, 2018

43 Zhou Q-H, "Receptor-mediated abeta amyloid antibody targeting to Alzheimer’s disease mouse brain" 8 : 280-285, 2011

44 Perry T, "Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4" 302 : 881-888, 2002

45 Hölscher C, "Potential role of glucagon-like peptide-1(GLP-1)in neuroprotection" 26 : 871-882, 2012

46 Ng RC-L, "Potential neuroprotective effects of adiponectin in Alzheimer’s disease" 18 : 592-, 2017

47 Popelova A, "Potential neuroprotective and anti-apoptotic properties of a long-lasting stable analog of ghrelin : an in vitro study using SH-SY5Y cells" 67 : 339-346, 2018

48 Shen J, "Poly(ethylene glycol)-block-poly(D, L-lactide acid)micelles anchored with angiopep-2 for brain-targeting delivery" 19 : 197-203, 2011

49 Boado RJ, "Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor" 7 : 237-244, 2010

50 최훈지 ; 조영민, "Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists" 대한내분비학회 36 (36): 22-29, 2021

51 Xia H, "Penetratin-functionalized PEG–PLA nanoparticles for brain drug delivery" 436 : 840-850, 2012

52 Ali T, "Osmotin attenuates amyloid beta-induced memory impairment, tau phosphorylation and neurodegeneration in the mouse hippocampus" 5 : 11708-, 2015

53 Novakovic ZM, "Oral delivery of mouse [d-Leu-4]-OB3, a synthetic peptide amide with leptinlike activity, in male C57BL/6J wild-type and ob/ob mice : effects on energy balance, glycaemic control and serum osteocalcin levels" 12 : 532-539, 2010

54 Anderson BM, "Oral delivery of [D-Leu-4]-OB3 and MA-[D-Leu-4]-OB3, synthetic peptide leptin mimetics : immunofluorescent localization in the mouse hypothalamus" 1664 : 1-8, 2017

55 Zhao P, "Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin’s effects on food intake" 577 : 432-436, 2020

56 Zhang JV, "Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin’s effects on food intake" 310 : 996-999, 2005

57 Pradhan G, "Obestatin stimulates glucose-induced insulin secretion through ghrelin receptor GHS-R" 7 : 979-, 2017

58 Gargantini E, "Obestatin promotes proliferation and survival of adult hippocampal progenitors and reduces amyloid-β-induced toxicity" 422 : 18-30, 2016

59 Erşahin M, "Obestatin alleviates subarachnoid haemorrhage-induced oxidative injury in rats via its anti-apoptotic and antioxidant effects" 27 : 1181-1189, 2013

60 Shah SA, "Novel osmotin inhibits SREBP2 via the AdipoR1/AMPK/SIRT1 pathway to improve Alzheimer’s disease neuropathological deficits" 22 : 407-416, 2017

61 Calsolaro V, "Novel GLP-1(glucagon-like peptide-1)analogues and insulin in the treatment for Alzheimer’s disease and other neurodegenerative diseases" 29 : 1023-1039, 2015

62 Zhang Y, "Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter" 15 : 339-350, 2004

63 Roujeau C, "New pharmacological perspectives for the leptin receptor in the treatment of obesity" 5 : 167-, 2014

64 Resende R, "New BACE1 chimeric peptide inhibitors selectively prevent AβPP-β cleavage decreasing amyloid-β production and accumulation in Alzheimer’s disease models" 76 : 1317-1337, 2020

65 Tai J, "Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer’s disease" 1678 : 64-74, 2018

66 Salles GN, "Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1single agonist in Alzheimer’s disease" 162 : 107813-, 2020

67 Batista AF, "Neuroprotective actions of glucagon-like peptide-1(GLP-1)analogues in Alzheimer’s and Parkinson’s diseases" 33 : 209-223, 2019

68 Rodrigues BDS, "Nerve growth factor gene delivery across the blood-brain barrier to reduce beta amyloid accumulation in AD mice" 17 : 2054-2063, 2020

69 Ko YT, "Nanoparticle-mediated delivery of oligonucleotides to the blood–brain barrier : in vitro and in situ brain perfusion studies on the uptake mechanisms" 21 : 866-873, 2013

70 Saraiva C, "Nanoparticle-mediated brain drug delivery : overcoming blood–brain barrier to treat neurodegenerative diseases" 235 : 34-47, 2016

71 Minalyan A, "Multiple beneficial effects of ghrelin agonist, HM01 on homeostasis alterations in 6-hydroxydopamine model of Parkinson’s disease in male rats" 13 : 13-, 2019

72 Mourtas S, "Multifunctional nanoliposomes with curcumin–lipid derivative and brain targeting functionality with potential applications for Alzheimer disease" 80 : 175-183, 2014

73 Papadia K, "Multifunctional LUV liposomes decorated for BBB and amyloid targeting-B. In vivo brain targeting potential in wild-type and APP/PS1 mice" 102 : 180-187, 2017

74 Crombez D, "Modulation of adiponectin receptors AdipoR1 and AdipoR2 by phage display-derived peptides in in vitro and in vivo models" 28 : 831-851, 2020

75 Tramutola A, "Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer’s disease pathology" 17 : 59-75, 2017

76 Shah Brijesh, "Microemulsion as a promising carrier for nose to brain delivery: journey since last decade" 한국약제학회 51 (51): 611-634, 2021

77 Tian J, "MK0677, a ghrelin mimetic, improves neurogenesis but fails to prevent hippocampal lesions in a mouse model of Alzheimer’s disease pathology" 72 : 467-478, 2019

78 Jeong Y-O, "MK-0677, a ghrelin agonist, alleviates amyloid beta-related pathology in 5XFAD mice, an animal model of Alzheimer’s disease" 19 : 1800-, 2018

79 Anderson BM, "MA-[d-Leu-4]-OB3, a small molecule synthetic peptide leptin mimetic, mirrors the cognitive enhancing action of leptin in a mouse model of type 1 diabetes mellitus and Alzheimer’s disease-like cognitive impairment" 26 : 1243-1249, 2020

80 Hirschstein Z, "MA-[D-Leu-4]-OB3, a small molecule synthetic peptide leptin mimetic, improves episodic memory, and reduces serum levels of tumor necrosis factor-alpha and neurodegeneration in mouse models of Type 1 and Type 2 Diabetes Mellitus" 1864 : 129697-, 2020

81 Johnston JM, "Low plasma leptin in cognitively impaired ADNI subjects : gender differences and diagnostic and therapeutic potential" 11 : 165-174, 2014

82 Yin H, "Low plasma leptin and high soluble leptin receptor levels are associated with mild cognitive impairment in type 2 diabetic patients" 10 : 132-, 2018

83 Kołodziejski PA, "Long-term obestatin treatment of mice type 2 diabetes increases insulin sensitivity and improves liver function" 56 : 538-550, 2017

84 Park K-A, "Long-lasting exendin-4 fusion protein improves memory deficits in high-fat diet/streptozotocin-induced diabetic mice" 12 : 159-, 2020

85 Mercer JG, "Localization of leptin receptor mRNA and the long form splice variant(Ob-Rb)in mouse hypothalamus and adjacent brain regions by in situ hybridization" 387 : 113-116, 1996

86 Han W-N, "Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats" 34 : 576-588, 2013

87 Vadini F, "Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes : a randomized, controlled study" 44 : 1254-1263, 2020

88 Kohno D, "Leptin suppresses ghrelin-induced activation of neuropeptide Y neurons in the arcuate nucleus via phosphatidylinositol 3-kinaseand phosphodiesterase 3-mediated pathway" 148 : 2251-2263, 2007

89 Greco SJ, "Leptin reduces Alzheimer’s disease-related tau phosphorylation in neuronal cells" 376 : 536-541, 2008

90 Doherty GH, "Leptin prevents hippocampal synaptic disruption and neuronal cell death induced by amyloid beta" 34 : 226-237, 2013

91 Oomura Y, "Leptin facilitates learning and memory performance and enhances hippocampal CA1 long-term potentiation and CaMK II phosphorylation in rats" 27 : 2738-2749, 2006

92 Tong JQ, "Leptin attenuates the detrimental effects of beta-amyloid on spatial memory and hippocampal later-phase long term potentiation in rats" 73 : 125-130, 2015

93 Pflanzner T, "LRP1 mediates bidirectional transcytosis of amyloid-β across the blood-brain barrier" 32 : 2323-, 2011

94 Nazer B, "LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-β peptide in a blood–brain barrier in vitro model" 30 : 94-102, 2008

95 Eng J, "Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas" 267 : 7402-7405, 1992

96 Boado RJ, "Insulin receptor antibody–sulfamidase fusion protein penetrates the primate blood–brain barrier and reduces glycosoaminoglycans in Sanfilippo type A cells" 11 : 2928-2934, 2014

97 King MR, "Insulin deficiency, but not resistance, exaggerates cognitive deficits in transgenic mice expressing human amyloid and tau proteins. Reversal by Exendin-4 treatment" 98 : 2357-2369, 2020

98 Zhao W-Q, "Insulin and the insulin receptor in experimental models of learning and memory" 490 : 71-81, 2004

99 Ly PT, "Inhibition of GSK3betamediated BACE1 expression reduces Alzheimer-associated phenotypes" 123 : 224-235, 2013

100 Cao X, "Increased serum acylated ghrelin levels in patients with mild cognitive impairment" 61 : 545-552, 2018

101 Holubova M, "In vitro and in vivo characterization of novel stable peptidic ghrelin analogs : beneficial effects in the settings of lipopolysaccharide-induced anorexia in mice" 366 : 422-432, 2018

102 Abbas T, "Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice : Interaction between type 2 diabetes and Alzheimer’s disease" 205 : 265-271, 2009

103 Ramanathan A, "Impaired vascular-mediated clearance of brain amyloid beta in Alzheimer’s disease : the role, regulation and restoration of LRP1" 7 : 136-, 2015

104 Chua L-M, "Impaired neuronal insulin signaling precedes Aβ 42Accumulation in female AβPPsw/PS1ΔE9 Mice" 29 : 783-791, 2012

105 Boado RJ, "IgG-single chain Fv fusion protein therapeutic for alzheimer’s disease : Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey" 105 : 627-635, 2010

106 Boado RJ, "Humanization of anti-human insulin receptor antibody for drug targeting across the human blood–brain barrier" 96 : 381-391, 2007

107 Pardridge WM, "Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood–brain barrier in vivo in the primate" 12 : 807-816, 1995

108 Moult PR, "Hormonal regulation of hippocampal dendritic morphology and synaptic plasticity" 2 : 269-275, 2008

109 Mcnay EC, "Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance" 93 : 546-553, 2010

110 Kuo Y-C, "Glutathione-and apolipoprotein E-grafted liposomes to regulate mitogen-activated protein kinases and rescue neurons in Alzheimer’s disease" 127 : 112233-, 2021

111 Ma T, "Glucagonlike peptide-1 cleavage product GLP-1(9–36)amide rescues synaptic plasticity and memory deficits in Alzheimer’s disease model mice" 32 : 13701-13708, 2012

112 Zhang J, "Glucagon-like peptide-1receptor agonist Exendin-4 improves neurological outcomes by attenuating TBI-induced inflammatory responses and MAPK activation in rats" 86 : 106715-, 2020

113 Holst JJ, "Glucagon-like peptide-1, glucose homeostasis and diabetes" 14 : 161-168, 2008

114 Perry T, "Glucagon-like peptide-1 decreases endogenous amyloid-β peptide(Aβ)levels and protects hippocampal neurons from death induced by Aβ and iron" 72 : 603-612, 2003

115 Bonfili L, "Ghrelin induces apoptosis in colon adenocarcinoma cells via proteasome inhibition and autophagy induction" 18 : 1188-1200, 2013

116 Jeon SG, "Ghrelin in Alzheimer’s disease : pathologic roles and therapeutic implications" 55 : 100945-, 2019

117 Diano S, "Ghrelin controls hippocampal spine synapse density and memory performance" 9 : 381-388, 2006

118 Huang J, "Ghrelin attenuates oxidative stress and neuronal apoptosis via GHSR-1alpha/AMPK/Sirt1/PGC-1alpha/UCP2 pathway in a rat model of neonatal HIE" 141 : 322-337, 2019

119 Shi L, "Ghrelin and neurodegenerative disorders-a review" 54 : 1144-1155, 2017

120 Kunath N, "Ghrelin agonist does not foster insulin resistance but improves cognition in an Alzheimer’s disease mouse model" 5 : 11452-, 2015

121 Chiorazzi A, "Ghrelin agonist HM01attenuates chemotherapy-induced neurotoxicity in rodent models" 840 : 89-103, 2018

122 Takahashi M, "Genomic structure and mutations in adipose-specific gene, adiponectin" 24 : 861-868, 2000

123 Lee JY, "Genetic engineering of novel super long-acting Exendin-4 chimeric protein for effective treatment of metabolic and cognitive complications of obesity" 257 : 120-250, 2020

124 Shibata N, "Genetic association between ghrelin polymorphisms and Alzheimer’s disease in a Japanese population" 32 : 178-181, 2011

125 Arora S, "GLUT-1 : an effective target to deliver brain-derived neurotrophic factor gene across the blood brain barrier" 11 : 1620-1633, 2020

126 Boado RJ, "Fusion antibody for Alzheimer’s disease with bidirectional transport across the blood-brain barrier and Aβ fibril disaggregation" 18 : 447-455, 2007

127 Hatakeyama H, "Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo" 281 : 25-33, 2004

128 Savioz A, "Expression of leptin receptor mRNA(long form splice variant)in the human cerebellum" 8 : 3123-3126, 1997

129 Bu G, "Expression and function of the low density lipoprotein receptor-related protein(LRP)in mammalian central neurons" 269 : 18521-18528, 1994

130 Ahn Y-J, "Exendin-4 pretreatment attenuates kainic acid-induced hippocampal neuronal death" 10 : 2527-, 2021

131 Garabadu D, "Exendin-4 attenuates brain mitochondrial toxicity through PI3K/Akt-dependent pathway in amyloid beta(1–42)-induced cognitive deficit rats" 128 : 39-49, 2019

132 Choudhari M, "Evolving new-age strategies to transport therapeutics across the blood-brain-barrier" 599 : 120351-, 2021

133 Denver RJ, "Evolution of leptin structure and function" 94 : 21-38, 2011

134 Valcarce C, "Effects of the oral, small molecule GLP-1R agonist TTP273 on patients with stage 2 hypertension : results from a post hoc analysis of the phase 2 logra study" 68 : 1015-, 2019

135 Kamei N, "Effective nose-to-brain delivery of exendin-4via coadministration with cell-penetrating peptides for improving progressive cognitive dysfunction" 8 : 1-14, 2018

136 Kamei N, "Effect of an enhanced nose-to-brain delivery of insulin on mild and progressive memory loss in the senescence-accelerated mouse" 14 : 916-927, 2017

137 Wu D, "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor" 100 : 1804-1812, 1997

138 Banks WA, "Drug delivery to the brain in Alzheimer’s disease : consideration of the blood–brain barrier" 64 : 629-639, 2012

139 Amatya R, "Drug delivery strategies for enhancing the therapeutic efficacy of toxin-derived antidiabetic peptides" 12 : 313-, 2020

140 Pardridge WM, "Drug and gene targeting to the brain with molecular Trojan horses" 1 : 131-139, 2002

141 Guan XM, "Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues" 48 : 23-29, 1997

142 Willard FS, "Discovery and pharmacology of the covalent GLP-1 receptor(GLP-1R)allosteric modulator BETP : A novel tool to probe GLP-1R pharmacology" 88 : 173-191, 2020

143 Sumbria RK, "Disaggregation of amyloid plaque in brain of Alzheimer’s disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Abeta amyloid peptide" 10 : 3507-3513, 2013

144 Petri M, "Diabetic gastroparesis : an overview of pathogenesis, clinical presentation and novel therapies, with a focus on ghrelin receptor agonists" 35 : 107-733, 2021

145 Duwa Ramesh ; 정지헌 ; Yook, Simmyung, "Development of immunotherapy and nanoparticles-based strategies for the treatment of Parkinson’s disease" 한국약제학회 51 (51): 465-481, 2021

146 Emami J, "Development and optimization of transferrin-conjugated nanostructured lipid carriers for brain delivery of paclitaxel using Box-Behnken design" 22 : 370-382, 2017

147 Singh VK, "Development and characterization of lysine-methotrexate conjugate for enhanced brain delivery" 23 : 2327-2337, 2016

148 Rozhavskaya-Arena M, "Design of a synthetic leptin agonist : effects on energy balance, glucose homeostasis, and thermoregulation" 141 : 2501-2507, 2000

149 Arora S, "Design and validation of liposomal ApoE2 gene delivery system to evade blood–brain barrier for effective treatment of Alzheimer’s disease" 18 : 714-725, 2020

150 Jolivalt CG, "Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice : parallels with Alzheimer’s disease and correction by insulin" 86 : 3265-3274, 2008

151 Saxena AR, "Danuglipron(PF-06882961)in type 2 diabetes : a randomized, placebo-controlled, multiple ascending-dose phase 1 trial" 27 : 1079-1087, 2021

152 Cao Y, "DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer’s disease" 827 : 215-226, 2018

153 Demeule M, "Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties" 124 : 1199-1213, 2014

154 Breijyeh Z, "Comprehensive review on Alzheimer’s disease : causes and treatment" 25 : 5789-, 2020

155 Ng RC-L, "Chronic oral administration of adipoRon reverses cognitive impairments and ameliorates neuropathology in an Alzheimer’s disease mouse model" 26 : 5669-5689, 2020

156 Eslami M, "Chronic ghrelin administration restores hippocampal long-term potentiation and ameliorates memory impairment in rat model of Alzheimer’s disease" 28 : 724-734, 2018

157 Ng RC-L, "Chronic adiponectin deficiency leads to Alzheimer’s disease-like cognitive impairments and pathologies through AMPK inactivation and cerebral insulin resistance in aged mice" 11 : 71-, 2016

158 Cheng Z, "Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis-and Alzheimer’s disease-related animal models despite reported blood-brain barrier disruption" 38 : 1355-1361, 2010

159 Shin MC, "Cell-penetrating peptides : achievements and challenges in application for cancer treatment" 102 : 575-587, 2014

160 Mohamed Safaa H. ; Shahat Abdelaaty A. ; Mohamed Mohamed Ragaa ; Khalil Wagdy K. B. ; Salem Ahmed M. ; Farrag Abdel Razik H. ; Ahmed Hanaa Hamdy, "Camellia sinesis leaves extract ameliorates high fat diet-induced nonalcoholic steatohepatitis in rats: analysis of potential mechanisms" 한국약제학회 51 (51): 183-197, 2021

161 Huwyler J, "Brain drug delivery of small molecules using immunoliposomes" 93 : 14164-14169, 1996

162 Yu YJ, "Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target" 3 : 84-, 2011

163 Erickson MA, "Blood–brain barrier dysfunction as a cause and consequence of Alzheimer’s disease" 33 : 1500-1513, 2013

164 Friden PM, "Blood-brain barrier penetration and in vivo activity of an NGF conjugate" 259 : 373-377, 1993

165 Boado RJ, "Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey" 24 : 1741-1749, 2013

166 Nehra G, "Blood-brain barrier leakage in Alzheimer’s disease : from discovery to clinical relevance" 234 : 108-119, 2022

167 Pardridge WM, "Blood-brain barrier drug targeting : the future of brain drug development" 3 : 90-105, 2003

168 Pardridge WM, "Blood-brain barrier and delivery of protein and gene therapeutics to brain" 11 : 373-, 2020

169 Hultqvist G, "Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor" 7 : 308-318, 2017

170 Lieb W, "Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging" 302 : 2565-2572, 2009

171 Topal GR, "ApoE-targeting increases the transfer of solid lipid nanoparticles with donepezil cargo across a culture model of the blood–brain barrier" 13 : 38-, 2021

172 Dos Santos RB, "ApoE-2 brain-targeted gene therapy through transferrin and penetratin tagged liposomal nanoparticles" 36 : 161-, 2019

173 Neves AR, "Apo E-functionalization of solid lipid nanoparticles enhances brain drug delivery : uptake mechanism and transport pathways" 28 : 995-1004, 2017

174 Bendlin BB, "Antidiabetic therapies and Alzheimer disease" 21 : 83-91, 2019

175 Friden PM, "Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier" 88 : 4771-4775, 1991

176 Markoutsa E, "Anti-Aβ-MAb and dually decorated nanoliposomes : effect of Aβ1-42 peptides on interaction with hCMEC/D3 cells" 81 : 49-56, 2012

177 Shao K, "Angiopep-2modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain" 147 : 118-126, 2010

178 Liu Q, "Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1" 56 : 66-78, 2007

179 Cummings J, "Alzheimer’s disease drug development pipeline : 2020" 6 : e12050-, 2020

180 Cummings J, "Aducanumab produced a clinically meaningful benefit in association with amyloid lowering" 13 : 98-, 2021

181 Ali T, "Adiponectin-mimetic novel nonapeptide rescues aberrant neuronal metabolic-associated memory deficits in Alzheimer’s disease" 16 : 23-, 2021

182 Wang C, "Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine phosphorylation of IRS-1" 282 : 7991-7996, 2007

183 Liu Z, "Adiponectin reduces ER stress-induced apoptosis through PPAR α transcriptional regulation of ATF2 in mouse adipose" 7 : e2487-, 2016

184 Song J, "Adiponectin receptor-mediated signaling ameliorates cerebral cell damage and regulates the neurogenesis of neural stem cells at high glucose concentrations : an in vivo and in vitro study" 6 : e1844-, 2015

185 Thundyil J, "Adiponectin receptor signalling in the brain" 165 : 313-327, 2012

186 Pousti F, "Adiponectin modulates synaptic plasticity in hippocampal dentate gyrus" 662 : 227-232, 2018

187 Chan K-H, "Adiponectin is protective against oxidative stress induced cytotoxicity in amyloid-beta neurotoxicity" 7 : e52354-, 2012

188 Miao W, "Adiponectin ameliorates hypoperfusive cognitive deficits by boosting a neuroprotective microglial response" 205 : 102125-, 2021

189 Liu B, "AdipoRon improves cognitive dysfunction of Alzheimer’s disease and rescues impaired neural stem cell proliferation through AdipoR1/AMPK pathway" 327 : 113249-, 2020

190 Couch JA, "Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier" 5 : 183-, 2013

191 Regina A, "ANG4043, a novel brain-penetrant peptide–mAb conjugate, is efficacious against HER2-positive intracranial tumors in mice" 14 : 129-140, 2015

192 Okada-Iwabu M, "A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity" 503 : 493-499, 2013

193 Shi L, "A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer ICV" 327 : 65-74, 2017

194 Perry TA, "A new Alzheimer’s disease interventive strategy : GLP-1" 5 : 565-571, 2004

195 Malekizadeh Y, "A leptin fragment mirrors the cognitive enhancing and neuroprotective actions of leptin" 27 : 4769-4782, 2017